IGI, 10%
TAK-339-3001
Phase 3 mab active
Quick answer
IGI, 10% for Multiple Myeloma is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Multiple Myeloma
- Phase
- Phase 3
- Modality
- mab
- Status
- active